share_log

HC Wainwright & Co. Reiterates Buy on Day One Biopharmaceutical, Maintains $40 Price Target

Benzinga ·  Aug 1 18:32  · Ratings

HC Wainwright & Co. analyst Andres Maldonado reiterates Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and maintains $40 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment